研究者業績

安井 稔博

ヤスイ トシヒロ  (yasui toshihiro)

基本情報

所属
藤田医科大学 医学部 医学科 小児外科学 講師 (Senior Assistant Professor)
学位
学士(医学)

J-GLOBAL ID
201501009575646720
researchmap会員ID
7000012894

論文

 90

MISC

 16
  • Atsuki Naoe, Tomonori Tsuchiya, Yasuhiro Kondo, Naoko Uga, Shunsuke Watanabe, Toshihiro Yasui, Fujio Hara, Tatsuya Suzuki
    Pediatric surgery international 35(6) 723-728 2019年6月  
    PURPOSE: Arctigenin has been shown to have anti-tumor effects in various types of cancers. This study was conducted to verify these effects in the human-derived hepatoblastoma cell line, HUH-6 clone 5 (hereinafter, HUH-6). METHODS: Arctigenin was added to cultured HUH-6 cells, and cellular activity was evaluated by MTS assay. To determine the relationship between reduced cellular activity and apoptosis, we measured the activities of caspase 3/7, 8, and 9 and conducted flow cytometry with Annexin V/PI staining. RESULTS: The MTS assay revealed that cellular activity decreased after arctigenin treatment in a concentration-dependent manner (IC50 = 4 µM). To investigate apoptosis induction, activity assays of caspase 3/7, 8, and 9 were performed. While caspase 3/7 and 8 exhibited high activity, caspase 9 showed no activity. Thus, apoptosis induction may have involved the action of tumor necrosis factor receptor 1 (TNFR1). Flow cytometry conducted with Annexin V/PI staining revealed the occurrence of early apoptosis. CONCLUSION: We found that arctigenin has anti-tumor effects in HUH-6 cells in a concentration-dependent manner. Arctigenin may have exerted its anti-tumor effect by inducing apoptosis via TNFR1, which recruits Complex IIa to activate caspase 8 and 3/7. These results may be useful for developing therapeutic agents for hepatoblastoma.
  • 宇賀 菜緒子, 土屋 智寛, 近藤 靖浩, 直江 篤樹, 渡邉 俊介, 安井 稔博, 原 普二夫, 鈴木 達也, 中谷 直史, 土田 邦博, 吉村 文, 熊本 海生航, 長尾 静子
    日本小児外科学会雑誌 55(3) 674-674 2019年5月  
  • Shunsuke Watanabe, Tatsuya Suzuki, Yasuhiro Kondo, Atsuki Naoe, Naoko Uga, Toshihiro Yasui, Fujio Hara, Tomonori Tsuchiya
    Minerva pediatrica 2019年1月2日  
    BACKGROUND: Neuroblastoma (NB) is a pediatric malignant solid tumor characterized as refractory cancer with poor prognosis. Mitosis-karyorrhexis index (MKI) is a prognostic factor but is prone to observer bias. The usefulness of MKI with Ki-67, as a marker of malignancy, was investigated. The efficacy of molecular-targeted therapeutic agents with fewer side effects in tumors has been studied. Molecular-targeted therapy targets include vascular endothelial growth factor (VEGF), involved in tumor angiogenesis; c-Kit, receptor of Kit/stem cells involved in tumor growth, vasculature, and lymphangiogenesis; platelet-derived growth factor receptor (PDGFR); and B-Raf proto-oncogene, serine/threonine kinase (BRAF), involved in the RAS protein-mediated mitogen-activated protein kinase pathway. Therefore, expression profiles of these factors and growth inhibitory effects of molecular-targeted drugs against NB were investigated. METHODS: Ten frozen NB tissue samples collected during January 1993-December 2017 were evaluated immunohistochemically for Ki-67 and VEGF. c-Kit, PDGFR, and BRAF expression levels were evaluated using enzyme-linked immunosorbent assays; relationships between these factors and clinicopathological parameters of NB were analyzed. RESULTS: Eight patients with NB showed no amplification of MYCN (MYCN proto- oncogene, bHLH transcription factor). There were two cases of ganglioneuroblastoma (GNB). More NB cells were positive for Ki-67 than for GNB cells. VEGF expression was observed in all NB specimens and was stronger in stage IIB and higher. No BRAF or c-Kit activity was observed; PDGFR activity was greater in NB than in GNB (p = 0.02). CONCLUSIONS: Thus, Ki-67 may help evaluate NB malignancy. As the first therapy for NB prevents amplification of MYCN, agents targeting PDGFR as well as VGFG can inhibit NB cell proliferation.
  • 水谷 修平, 星野 伸, 竹内 陽平, 隈井 すみれ, 尾池 直子, 奥村 俊彦, 前田 徹, 小林 貴江, 足達 武憲, 小出 照子, 河邊 太加志, 横井 克幸, 中島 葉子, 伊藤 哲哉, 安井 稔博, 鈴木 達也
    日本小児科学会雑誌 122(1) 118-118 2018年1月  
  • 星野 伸, 隈井 すみれ, 前田 徹, 足達 武憲, 河邊 太加志, 横井 克幸, 中島 葉子, 伊藤 哲哉, 安井 稔博, 鈴木 達也
    日本先天代謝異常学会雑誌 33 221-221 2017年9月  

講演・口頭発表等

 16

教育内容・方法の工夫(授業評価等を含む)

 1
  • 件名
    -
    終了年月日
    2013/11/05
    概要
    名古屋市立大学 学びなおし講座 感染症